RxDoctor Payments Data

Trevor Taylor, MD

Pulmonary Disease · Raleigh, NCNPI 1134548811

Payments from drug & device makers

$6,849in general payments, 2019–2025

Across 42 payments — averaging $163.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Pulmonx Corporation$2K
  • AstraZeneca$459
  • Boehringer Ingelheim$123
  • GSK$94
  • Abiomed$74
  • plus $76 from 4 others

What the payments were for

  • Travel & lodging$2,51937%
  • Food & beverage$1,29519%
  • Education$3,03644%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,849 in reported general payments places this provider in the 70th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$51,824
Medicare patients
192
Services billed
558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter243$169,480
Stiolto RespimatTiotropium Br/Olodaterol Hcl60$38,803
Breztri AerosphereBudesonide/Glycopyr/Formoterol52$33,512
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$22,864
Breo ElliptaFluticasone/Vilanterol33$14,423
Albuterol Sulfate HfaAlbuterol Sulfate190$4,528
BreynaBudesonide/Formoterol Fumarate16$3,603
Ventolin HfaAlbuterol Sulfate43$2,377
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$1,344
Montelukast Sodium58$958
Prednisone63$365
Fluticasone Propionate26$335
Azithromycin12$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$94$206,767314 claims
Boehringer IngelheimStiolto Respimat$123$38,80360 claims
AstraZenecaBreztri Aerosphere$459$33,51252 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →